Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
Targets |
NLRP3 NLRP3 inflammasome
|
---|---|
ln Vitro |
Compound 27, NLRP3-IN-8, has a notable anti-inflammatory effect, with an IC50 of 1.23 μM[1]. Using human liver microsomes, NLRP3-IN-8 demonstrates good metabolic stability (t1/2 = 138.63 min)[1]. Pyrolysis rate is considerably inhibited by NLRP3-IN-8 (0-10 μM, 1 h) in a concentration-dependent manner[1]. Only the activation of NLRP3 inflammasomes is inhibited by NLRP3-IN-8, which may also prevent the activation of inflammasomes by other inducers[1]. The NLRP3-induced ASC oligomerization is inhibited by NLRP3-IN-8[1]. By preventing NLRP3-NEK7 and NLRP3-ASC from interacting, NLRP3-IN-8 prevents the formation of NLRP3 inflammasomes[1].
|
ln Vivo |
NLRP3-IN-8 (compound 27; intragastric; 0–20 mg/kg; once daily, 7 days) substantially reduces the severity of colitis in mice caused by DSS[1].
|
Cell Assay |
Western Blot Analysis [1]
Cell Types: BMDMs cells Tested Concentrations: 0.5, 1, and 2 μM Incubation Duration: 30 min, pretreated with LPS (200 ng/mL) for 3 h Experimental Results: Dose-dependently blocked IL-1 b secretion and caspase-1 cleavage at concentrations of 0.5-2 μM. Inhibited the maturation of intracellular caspase-1 (p20), and did not affect the expression of other constituent proteins of NLRP3 inflammasome, such as pro-IL-1 β, pro-caspase-1 ( p45), NLRP3, ASC and NEK7. |
Animal Protocol |
Animal/Disease Models: DSS-induced acute colitis model in C57BL/6 male mice[1].
Doses: 20 mg/kg and 10 mg/kg dissolved in 0.5% sodium carboxymethyl cellulose aqueous solution. Route of Administration: intragastric (po) administration, one time/day, 7 days. Experimental Results: decreased the weight loss during the onset of colitis in mice, and diminished the disease activity index (DAI) in a dose-dependent manner. decreased colon shortening, pathological index score, the expression of TNF-a, IL-6 and IL-1 β in the tissues and inhibited the decrease of goblet cells. |
References |
[1]. Xing Xing Zhang, et al. Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis. Eur J Med Chem. 2022 Apr 7;236:114357.
|
Molecular Formula |
C23H20N2O6
|
---|---|
Molecular Weight |
420.41
|
CAS # |
2768650-56-0
|
SMILES |
C(C1C(=CC(=CC=1C=CC1C=CC(=CC=1)NC(C1OC=CC=1)=O)OC)OC)=CN(=O)=O |t:8,29|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3786 mL | 11.8932 mL | 23.7863 mL | |
5 mM | 0.4757 mL | 2.3786 mL | 4.7573 mL | |
10 mM | 0.2379 mL | 1.1893 mL | 2.3786 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.